Inhibition of proteasome activity prevents KSHV entry into endothelial cells and intracellular trafficking to nuclei.

<p>(A and C) HUVEC were treated with proteasome inhibitors MG132 (A) and EPOX (C) at indicated doses for 1 hr. Cells were then infected with KSHV in the presence of the inhibitors, fixed at 4 hpi, and stained for Orf65+ viral particles (red) and nuclei (blue). (B and D) Quantification of the total number of Orf65+ particles docked at each nucleus following treatment with proteasome inhibitors MG132 (B) and EPOX (D).